Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Breath or Urine Analysis May Indicate Disease

By LabMedica International staff writers
Posted on 18 Mar 2009
A sensor is being developed that will be able to analyze a patient's breath or urine to determine whether the patient has breast cancer, lung cancer, diabetes, or asthma. More...


The sensor device, known as the optofluidic ring resonator (OFRR), is an optical gas sensor that consists of a polymer-lined glass tube that guides the flow of a gas vapor, and a ring resonator that detects the molecules that pass through the glass tube. As the gas vapor enters the device, molecules in the vapor separate and react to the polymer lining. Light makes thousands of loops around the gas or liquid sample. The more the light loops around the sample, the more the light energy interacts with the gas vapor. These repetitive interactions enable the detection of a very small number of vapor molecules.

The device is being developed by Professor Xudong "Sherman" Fan, a University of Missouri (Columbia, MO, USA) scientist. It will analyze breath or urine samples for volatile markers inside the body that indicate disease. The markers, such as alkanes, acetones, or nitric oxide, give doctors information about what is happening inside the body and can be used as a diagnostic tool.

"Little traces of certain gas molecules in the breath or urine tell us if anything unusual is going on in the body," said Professor Fan. "Measuring these volatile markers would be a noninvasive way to determine if a disease is present without having to draw blood or complete a biopsy. In addition to the biomarkers already discovered, many more potential volatile markers are still under investigation."

Optical gas sensors have broad applications in the fields of medical care, industry, military, environment, and homeland security. In addition to OFRR's application in the medical industry, the device also can improve the detection of explosives on the battlefield. Currently, the existing gas vapor sensor technology is very bulky with equipment weighing more than 100 pounds and is difficult to use in the field.

"We hope to design a vapor sensor that has ultra-high sensitivity, specific and rapid response to a certain molecule, as well as the ability of on-the-spot chemical analyses, which usually requires the sensor to be small, portable, reusable, and have less power consumption," said Professor Fan.

Related Links:

University of Missouri



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
All-in-One Molecular System
AIO M160
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.